1. Home
  2. SSNC vs INSM Comparison

SSNC vs INSM Comparison

Compare SSNC & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSNC
  • INSM
  • Stock Information
  • Founded
  • SSNC 1986
  • INSM 1988
  • Country
  • SSNC United States
  • INSM United States
  • Employees
  • SSNC N/A
  • INSM N/A
  • Industry
  • SSNC EDP Services
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSNC Technology
  • INSM Health Care
  • Exchange
  • SSNC Nasdaq
  • INSM Nasdaq
  • Market Cap
  • SSNC 19.4B
  • INSM 17.3B
  • IPO Year
  • SSNC 1996
  • INSM 2000
  • Fundamental
  • Price
  • SSNC $79.47
  • INSM $102.68
  • Analyst Decision
  • SSNC Strong Buy
  • INSM Strong Buy
  • Analyst Count
  • SSNC 7
  • INSM 17
  • Target Price
  • SSNC $93.57
  • INSM $106.80
  • AVG Volume (30 Days)
  • SSNC 922.9K
  • INSM 4.1M
  • Earning Date
  • SSNC 07-24-2025
  • INSM 08-07-2025
  • Dividend Yield
  • SSNC 1.26%
  • INSM N/A
  • EPS Growth
  • SSNC 27.70
  • INSM N/A
  • EPS
  • SSNC 3.22
  • INSM N/A
  • Revenue
  • SSNC $5,960,900,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • SSNC $7.31
  • INSM $28.03
  • Revenue Next Year
  • SSNC $4.96
  • INSM $120.54
  • P/E Ratio
  • SSNC $24.65
  • INSM N/A
  • Revenue Growth
  • SSNC 6.92
  • INSM 20.77
  • 52 Week Low
  • SSNC $61.13
  • INSM $60.40
  • 52 Week High
  • SSNC $89.73
  • INSM $102.70
  • Technical
  • Relative Strength Index (RSI)
  • SSNC 48.06
  • INSM 78.76
  • Support Level
  • SSNC $78.92
  • INSM $98.46
  • Resistance Level
  • SSNC $80.58
  • INSM $102.00
  • Average True Range (ATR)
  • SSNC 1.28
  • INSM 3.50
  • MACD
  • SSNC -0.23
  • INSM 2.61
  • Stochastic Oscillator
  • SSNC 25.96
  • INSM 99.61

About SSNC SS&C Technologies Holdings Inc.

SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: